Replies to post #405839 on Anavex Life Sciences Corp (AVXL)

[frrol]

The company isn't withholding the AD results indefinitely. We'll be getting a proper topline and full results disclosure for our AD trial at some point. (The "top line" will be in the full results, eg, the tails, the ADL % mean change, etc.)

[sab63090]

Thanks....I am catching up on the posts & this is helpful...I recommended his last paragraph....lol...my bad!

[kevindenver]

The full KEM analysis is needed for the neurological trials as big claims require big evidence. This is particularly true since the goal is to prove the S1R/muscarinic mechanism of action will be applicable to multiple neurological indications. I also expect 3-71 to have equally thorough analysis build into the trial designs.

Also, $AVXL does not need EXCELLENCE to "save the day", but I'm sure it's fun to mention in the devil's advocate role.

Instead Anavex have blindsided the P2b/3 situation, continuing the deep work on the full KEM analysis in the background, while hopes of EXCELLENCE will save the day.

[WolfofMia]

Never I cant see your post because you are replying to someone in my ignore.

But at least you see admission of not getting proper TOP LINE DATA before JP, I wonder why IR told him/her otherwise.